







an Open Access Journal by MDPI

Rare Childhood Malignancy

Guest Editor:

Ass. Prof. Elizabeth M. Algar

- 1. Hudson Institute of Medical Research, Clayton, 3168, Australia
- 2. Department of Translational Medicine, Monash University, Clayton, 3168, Australia

Deadline for manuscript submissions:

closed (30 September 2020)

Message from the Guest Editor

Childhood cancer is a relatively rare disease; however, it is still a major cause of disease-related death in infants and children in countries of high economic status. Although five-year survival rates for many childhood cancers currently exceed 80%, there are several tumor groups for which survival rates remain persistently low. Tumor morphology, molecular subtype, age at diagnosis, disease stage, and tumor location are important factors influencing treatment outcomes.

The focus of this Special Issue is on highlighting biological and (pre)clinical studies on these less common pediatric cancers with comparatively poor outcomes, encompassing but not limited to studies advancing knowledge on tumor origin, tumor molecular genetics and epigenetics, biologically-based or targeted therapies, and tumor models, including organoids.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us